CEMIP and breast cancer: With UALCAN web tools, we again observed increased expression of CEMIP in BC relative to normal samples with statistical significance (p < 0.001) (Figure 1B) and further analyzed the expression level of CEMIP in BC based on subclasses (luminal, HER2+, and TNBC), individual cancer stages, patients’ age, nodal metastasis status, and TP53 mutation status between 114 normal and 1,097 primary BC of TCGA.